|
References | Type of trial | Patients | Administration | Immune response | Clinical responses |
|
CTL obtained from PBMC |
|
[35] | Phase I | HGG 2 newly diagnosed GBM, 2 recurrent GBM, 1 AOA | IC (7 to 13 injections) | | 2 PR (1 GBM, 1 AOA) No survival benefit (survival >2 years— AOA) |
|
[36] | Phase I | HGG 3 GBM, 1 AA | IC (3 injections) | | 3 PR (1 AA), 1 SD |
|
[37] | Phase I | recurrent HGG 7 GBM, 2 AA, 1 AOA | IC (3 injections) | | 1 CR (AA), 4 PR (3 GBM, 1 AA), 3 SD (GBM) Median survival: > 5 months |
|
[38] | Phase I | recurrent HGG 2 GBM, 1 AA, 2 AO | IC (3 to 11 injections) | Cerebrospinal fluid hypereosinophilia | 3 SD (1 AA, 2 AO) No survival benefit |
|
CTL obtained by lymphocytes from draining lymph nodes or PBMC after vaccination with irradiated ATC |
|
[40] | Phase I | recurrent HGG 12 GBM, 3 AA | IV (1 to 3 injections) | DTH (15/15) | No PR or SD Free disease survival: ≥ 8 months () (>40 months ) |
|
[41] | Phase I | recurrent HGG 9 GBM, 1 AA | IV (1 injection) | | 3 PR (1 AA, 2 GBM) Survival after reoperation: > 1 year () |
|
[42] | Pilot study | recurrent HGG 6 GBM, 3 GIII | IV intracarotid infusion (1 injection) | DTH (9/9) | 3 PR (1 GBM, 2 GIII with survival > 4 years) Correlation between clinical response and CD4/CD8 composition of infused cells. |
|
[43] | Phase I | newly diagnosed glioma: 6 GBM, 2 GII, 4 GIII | IV (1 to 2 injections) | | 4 PR (2 GBM, 2 GIII) 2 SD (2 GII) |
|
[44] | Pilot study | recurrent HGG16 GBM, 2 AA, 1 gliosarcoma | IV (1 injection) | DTH (17/19) | 1 CR, 7 PR, 9 SD Median survival: 12 months Correlation between survival and DTH response |
|
Autologous TIL |
|
[39] | Pilot study | HGG 3 GBM, 3 AA | IC (2 injections) | | 1 CR (AA), 2 PR (1 AA, 1 GBM) |
|